Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:9/10/2008

SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at two investor conferences in September:

-- Merriman Curhan Ford's 5th Annual Investor Summit to be held at the Mark Hopkins InterContinental Hotel in San Francisco on Monday, September 15, 2008 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time); and

-- UBS's 2008 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on Tuesday, September 23, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation date.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biolog
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
4. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
5. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
6. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
9. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
10. Halozyme Therapeutics Amends Stockholder Rights Plan
11. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Charles Darwin: More than the origin 2Charles Darwin: More than the origin 3Oceans day at International Climate Change Conference 2Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream 28TM 2920 Portable Bedside Monitors into the Masimo Patient SafetyNet 28TM 29 54210 1Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream 28TM 2920 Portable Bedside Monitors into the Masimo Patient SafetyNet 28TM 29 54210 2Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream 28TM 2920 Portable Bedside Monitors into the Masimo Patient SafetyNet 28TM 29 54210 3Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream 28TM 2920 Portable Bedside Monitors into the Masimo Patient SafetyNet 28TM 29 54210 4Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream 28TM 2920 Portable Bedside Monitors into the Masimo Patient SafetyNet 28TM 29 54210 5Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream 28TM 2920 Portable Bedside Monitors into the Masimo Patient SafetyNet 28TM 29 54210 6HDM Offers Solution to Health Care Fraud Cited by CNN and Health Plan Week 54205 1HDM Offers Solution to Health Care Fraud Cited by CNN and Health Plan Week 54205 2Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 1Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 2Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 3